Navigation Links
Trial Set to See if Drug Can Prevent Alzheimer's
Date:5/15/2012

TUESDAY, May 15 (HealthDay News) -- Researchers are preparing to test an experimental drug in people genetically primed to develop Alzheimer's disease.

The best-scenario hope is that the drug will lead to a way of preventing the progressive brain-wasting disease, and to a better understanding of its destructive processes, U.S. officials announced Tuesday.

The study volunteers will include some Americans as well as 300 members of an extended Colombian family -- some only 30 years old -- thought to have more relatives with Alzheimer's than any family in the world, The New York Times reported.

None of the study participants will have any signs of dementia at the start of the five-year, $100 million study. Dr. Francis Collins, director of the U.S. National Institutes of Health, said this study is "the first to focus on people who are cognitively normal but at very high risk for Alzheimer's disease," according to the Times.

People with a certain genetic mutation are predestined to develop early-onset Alzheimer's. For this group, dementia typically sets in by about age 50, and signs of thinking and memory problems are evident by age 45.

It's hoped that the study will reveal clues to the development and treatment of Alzheimer's -- the leading cause of dementia -- in other people as well, not just those with what doctors call early-onset Alzheimer's.

The trial is designed to test the widely held theory that Alzheimer's is caused by a buildup in the brain of a protein called beta amyloid. The experimental drug -- crenezumab, which is made by Genentech of South San Francisco -- is designed to attack the formation of beta amyloid plaque.

Currently, there is no cure for Alzheimer's, which affects 5.4 million Americans, or one in eight older adults. And as the baby boom generation ages, those numbers are expected to balloon, creating a major public health crisis in the United States.

Experts on Alzheimer's disease welcomed the announcement of the drug trial.

"This strategy is our best chance of success at Alzheimer's disease," said Dr. Sam Gandy, associate director of the Alzheimer's Disease Research Center at Mount Sinai School of Medicine and director of Mount Sinai's Center for Cognitive Health, in New York City.

"The main challenges are how to identify who is on their way to [Alzheimer's disease], how early we need to begin prior to symptoms, and how long we will have to run the trial before we can see whether the drug delays onset," added Gandy, chairman emeritus of the Alzheimer's Association's National Medical and Scientific Advisory Council.

More information

For more about Alzheimer's disease, visit the Alzheimer's Association.

-- HealthDay staff

SOURCES: Sam Gandy, M.D., Ph.D., Mount Sinai Chair in Alzheimer's Disease Research, and professor of neurology and psychiatry, and director, Mount Sinai Center for Cognitive Health, and associate director, Mount Sinai Alzheimer's Disease Research Center, Mount Sinai School of Medicine, New York City; The New York Times


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Palpitations are predictive of future atrial fibrillation
2. New Weight-Loss Drug Shows Promise in Trial
3. US spends far more for health care than 12 industrialized nations, but quality varies
4. Analysis Finds Clinical Trials Often Small, of Poor Quality
5. URMC clinical trial tests new regimen for hypertension
6. Brain Tumor Vaccine Shows Promise in Early Trial
7. Cancer trial information leaflets not fit for purpose- new study
8. Statin Alternative Looks Promising in Early Trials
9. Study: Low bone density medications may have protective effect on endometrial cancer
10. $4.2 million grant helps plan, launch first Alzheimers prevention trials
11. Cytori breast reconstruction cell therapy trial results published
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2017)... ... 22, 2017 , ... Phytocéane invites clients to take an exotic journey deep ... with ZANZIBAR MILKY CREAM. Inspired by the beauty of Zanzibar, a Tanzanian archipelago off ... moisturizing vegetal coral to create this gentle, velvety body cream to envelop the skin ...
(Date:1/22/2017)... , ... January 22, 2017 , ... Medical lab ... results. Often the results of a simple test will take days to arrive to ... Test Now offers customers direct access to their lab tests, bypassing the cost and ...
(Date:1/21/2017)... ... 2017 , ... "ProDOF is the perfect set of tools for video editors that want to ... said Christina Austin - CEO of Pixel Film Studios. , Video editors using ProDOF ... of a DSLR racking focus from one area into the next. ProDOF comes with ...
(Date:1/21/2017)... Barbara, CA (PRWEB) , ... January 21, 2017 ... ... its Director of Alumni Relations, Dianne Travis-Teague, the electrifying line-up of events for ... festivities for alumni, family, friends, and community. “Coming Home 2017” will be ...
(Date:1/21/2017)... (PRWEB) , ... January 21, 2017 , ... In the ... when individuals experience the freedom of recovery, they often feel shame for having struggled ... post-traumatic stress disorder (PTSD). In the workshop, “Rising Strong in Life After an Eating ...
Breaking Medicine News(10 mins):
(Date:1/23/2017)... , Jan. 23, 2017  Using Astute Medical,s ... high risk for acute kidney injury (AKI) after ... globally-recognized care guidelines significantly improved outcomes ... AKI more than 33 percent, according to a ... journal Intensive Care Medicine. ...
(Date:1/23/2017)... Longer life expectancy and rising healthcare expenditure in developing countries are factors ... BCC Research reveals in its new report that markets in developing ... strong growth due to rising government healthcare spending, increased levels of healthcare ... Reading ... BCC ...
(Date:1/23/2017)... 2017 NeuroVive Pharmaceutical AB (Nasdaq Stockholm: ... preclinical collaboration agreement with the Children,s Hospital of ... M.D., a US key opinion leader in the mitochondrial medicine ... ... from NeuroVive,s research program, NVP015, in certain experimental disease models. ...
Breaking Medicine Technology: